{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:21:55Z","timestamp":1778620915294,"version":"3.51.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000121","name":"Division of Mathematical Sciences","doi-asserted-by":"publisher","award":["0931642"],"award-info":[{"award-number":["0931642"]}],"id":[{"id":"10.13039\/100000121","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["11501568"],"award-info":[{"award-number":["11501568"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Syst Biol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12918-019-0706-y","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T21:03:21Z","timestamp":1553115801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["How to schedule VEGF and PD-1 inhibitors in combination cancer therapy?"],"prefix":"10.1186","volume":"13","author":[{"given":"Xiulan","family":"Lai","sequence":"first","affiliation":[]},{"given":"Avner","family":"Friedman","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,3,13]]},"reference":[{"issue":"10","key":"706_CR1","doi-asserted-by":"publisher","first-page":"006577","DOI":"10.1101\/cshperspect.a006577","volume":"2","author":"KL Meadows","year":"2012","unstructured":"Meadows KL, Hurwitz HI. Anti-vegf therapies in the clinic. Cold Spring Harb Perspect Med. 2012; 2(10):006577.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"706_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40880-016-0123-1","volume":"35","author":"IF Nerini","year":"2016","unstructured":"Nerini IF, Cesca M, Bizzaro F, Giavazzi R. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. Chin J Cancer. 2016; 35(1):61.","journal-title":"Chin J Cancer"},{"issue":"12","key":"706_CR3","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1158\/1078-0432.CCR-11-3000","volume":"18","author":"RS Turley","year":"2012","unstructured":"Turley RS, Fontanella AN, Padussis JC, Toshimitsu H, Tokuhisa Y, Cho EH, Hanna G, Beasley GM, Augustine CK, Dewhirst MW, et al.Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma. Clin Cancer Res. 2012; 18(12):3328\u201339.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"706_CR4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/1535-7163.MCT-11-0742-T","volume":"11","author":"CV Pastuskovas","year":"2012","unstructured":"Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, et al.Effects of anti-vegf on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther. 2012; 11(3):752\u201362.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"706_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/10739680490457665","volume":"11","author":"HE Daldrup-Link","year":"2004","unstructured":"Daldrup-Link HE, Okuhata Y, Wolfe A, Srivastav S, \u00d8ie S, Ferrara N, Cohen RL, Shames DM, Brasch RC. Decrease in tumor apparent permeability-surface area product to a mri macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation. Microcirculation. 2004; 11(5):387\u201396.","journal-title":"Microcirculation"},{"issue":"1","key":"706_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/1535-7163.MCT-15-0063","volume":"15","author":"M Cesca","year":"2016","unstructured":"Cesca M, Morosi L, Berndt A, Nerini IF, Frapolli R, Richter P, Decio A, Dirsch O, Micotti E, Giordano S, et al.Bevacizumab-induced inhibition of angiogenesis promotes a more homogeneous intratumoral distribution of paclitaxel, improving the antitumor response. Mol Cancer Ther. 2016; 15(1):125\u201335.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"706_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase ii, randomized trial comparing bevacizumab plus fluorouracil (fu)\/leucovorin (lv) with fu\/lv alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003; 21(1):60\u20135.","journal-title":"J Clin Oncol"},{"issue":"12","key":"706_CR8","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/sj.bjc.6601005","volume":"88","author":"H Wildiers","year":"2003","unstructured":"Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, De Bruijn E, Van Oosterom A. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of cpt-11. Br J Cancer. 2003; 88(12):1979.","journal-title":"Br J Cancer"},{"issue":"2","key":"706_CR9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/jrr\/rrs102","volume":"54","author":"Y Liu","year":"2012","unstructured":"Liu Y, Suzuki M, Masunaga S-i, Chen Y-W, Kashino G, Tanaka H, Sakurai Y, Kirihata M, Ono K. Effect of bevacizumab treatment on p-boronophenylalanine distribution in murine tumor. J Radiat Res. 2012; 54(2):260\u20137.","journal-title":"J Radiat Res"},{"issue":"1","key":"706_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ccr.2011.11.023","volume":"21","author":"AA Van der Veldt","year":"2012","unstructured":"Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, et al.Rapid decrease in delivery of chemotherapy to tumors after anti-vegf therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell. 2012; 21(1):82\u201391.","journal-title":"Cancer Cell"},{"issue":"21","key":"706_CR11","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1158\/1078-0432.CCR-10-0669","volume":"16","author":"ML Maitland","year":"2010","unstructured":"Maitland ML, Hudoba C, Snider KL, Ratain MJ. Analysis of the yield of phase ii combination therapy trials in medical oncology. Clin Cancer Res. 2010; 16(21):5296\u2013302.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"706_CR12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/jnci\/djr218","volume":"103","author":"MR Sharma","year":"2011","unstructured":"Sharma MR, Stadler WM, Ratain MJ. Randomized phase ii trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011; 103(14):1093\u2013100.","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"706_CR13","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1158\/1078-0432.CCR-14-0521","volume":"20","author":"CJ Paller","year":"2014","unstructured":"Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, et al.Design of phase i combination trials: recommendations of the clinical trial design task force of the nci investigational drug steering committee. Clin Cancer Res. 2014; 20(16):4210\u20137.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"706_CR14","first-page":"0178479","volume":"12","author":"X Lai","year":"2017","unstructured":"Lai X, Friedman A. Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitor: A mathematical model. PLoS ONE. 2017; 12(2):0178479.","journal-title":"PLoS ONE"},{"issue":"70","key":"706_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12918-017-0446-9","volume":"11","author":"X Lai","year":"2017","unstructured":"Lai X, Friedman A. Combination therapy of cancer with braf inhibitor and immune checkpoint inhibitor: A mathematical model. BMC Syst Biol. 2017; 11(70):1\u201318. \n                    https:\/\/doi.org\/10.1186\/s12918-017-0446-9\n                    \n                  .","journal-title":"BMC Syst Biol"},{"issue":"12","key":"706_CR16","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","volume":"101","author":"JE Ohm","year":"2003","unstructured":"Ohm JE, Gabrilovich DI, Sempowski GD, Kisseleva E, Parman KS, Nadaf S, Carbone DP. Vegf inhibits t-cell development and may contribute to tumor-induced immune suppression. Blood. 2003; 101(12):4878\u201386.","journal-title":"Blood"},{"issue":"2","key":"706_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CJI.0b013e3181b91c9c","volume":"33","author":"JK Mulligan","year":"2010","unstructured":"Mulligan JK, Rosenzweig SA, Young MRI. Tumor secretion of vegf induces endothelial cells to suppress t cell functions through the production of pge2. J Immunother (Hagerstown, Md.: 1997). 2010; 33(2):126\u201335.","journal-title":"J Immunother (Hagerstown, Md.: 1997)"},{"issue":"11","key":"706_CR18","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/bjc.2012.468","volume":"107","author":"NG Gavalas","year":"2012","unstructured":"Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Ioannou K, Ziogas AC, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, et al.Vegf directly suppresses activation of t cells from ascites secondary to ovarian cancer via vegf receptor type 2. Br J Cancer. 2012; 107(11):1869\u201375.","journal-title":"Br J Cancer"},{"issue":"4","key":"706_CR19","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ijc.26094","volume":"130","author":"AC Ziogas","year":"2012","unstructured":"Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, et al.Vegf directly suppresses activation of t cells from ovarian cancer patients and healthy individuals via vegf receptor type 2. Int J Cancer. 2012; 130(4):857\u201364.","journal-title":"Int J Cancer"},{"issue":"2","key":"706_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.20892\/j.issn.2095-3941.2015.0070","volume":"13","author":"Y-L Li","year":"2016","unstructured":"Li Y-L, Zhao H, Ren X-B. Relationship of vegf\/vegfr with immune and cancer cells: staggering or forward?. Cancer Biol Med. 2016; 13(2):206\u201314.","journal-title":"Cancer Biol Med"},{"key":"706_CR21","doi-asserted-by":"publisher","first-page":"12624","DOI":"10.1038\/ncomms12624","volume":"7","author":"JJ Wallin","year":"2016","unstructured":"Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, et al.Atezolizumab in combination with bevacizumab enhances antigen-specific t-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016; 7:12624.","journal-title":"Nat Commun"},{"issue":"2","key":"706_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10456-017-9550-0","volume":"20","author":"T Kuusk","year":"2017","unstructured":"Kuusk T, Albiges L, Escudier B, Grivas N, Haanen J, Powles T, Bex A. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. Angiogenesis. 2017; 20(2):205\u2013215.","journal-title":"Angiogenesis"},{"issue":"202","key":"706_CR23","first-page":"1","volume":"5","author":"PA Ott","year":"2015","unstructured":"Ott PA, Hodi FS, Buchbinder EI. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol. 2015; 5(202):1\u20137.","journal-title":"Front Oncol"},{"issue":"6","key":"706_CR24","first-page":"478","volume":"15","author":"DJ Einstein","year":"2017","unstructured":"Einstein DJ, McDermott DF. Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer. Clin Adv Hematol Oncol. 2017; 15(6):478\u201388.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"7","key":"706_CR25","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/sj.bjc.6604965","volume":"100","author":"C Alfaro","year":"2009","unstructured":"Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J, Palazon A, Hervas-Stubbs S, Gurpide A, Lopez-Picazo JM, et al.Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of vegf on human dendritic cell differentiation from monocytes. Br J Cancer. 2009; 100(7):1111\u20139.","journal-title":"Br J Cancer"},{"issue":"10","key":"706_CR26","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996; 2(10):1096\u2013103.","journal-title":"Nat Med"},{"issue":"2","key":"706_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet A-L, Latreche S, Bergaya S, Benhamouda N, Tanchot C, et al.Vegf-a modulates expression of inhibitory checkpoints on cd8+ t cells in tumors. J Exp Med. 2015; 212(2):139\u201348.","journal-title":"J Exp Med"},{"issue":"2","key":"706_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","volume":"73","author":"M Terme","year":"2013","unstructured":"Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, Dubreuil O, Carpentier AF, Tartour E, Taieb J. Vegfa-vegfr pathway blockade inhibits tumor-induced regulatory t-cell proliferation in colorectal cancer. Cancer Res. 2013; 73(2):539\u201349.","journal-title":"Cancer Res"},{"issue":"3","key":"706_CR29","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/cei.12069","volume":"172","author":"S Yasuda","year":"2013","unstructured":"Yasuda S, Sho M, Yamato I, Yoshiji H, Wakatsuki K, Nishiwada S, Yagita H, Nakajima Y. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (vegfr2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol. 2013; 172(3):500\u20136.","journal-title":"Clin Exp Immunol"},{"key":"706_CR30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1146\/annurev.immunol.021908.132603","volume":"28","author":"GP Sims","year":"2010","unstructured":"Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. Hmgb1 and rage in inflammation and cancer. Annu Rev Immunol. 2010; 28:367\u201388.","journal-title":"Annu Rev Immunol"},{"issue":"17","key":"706_CR31","doi-asserted-by":"publisher","first-page":"11621","DOI":"10.1074\/jbc.M113.449942","volume":"288","author":"L Zandarashvili","year":"2013","unstructured":"Zandarashvili L, Sahu D, Lee K, Lee YS, Singh P, Rajarathnam K, et al.Real-time kinetics of high-mobility group box 1 (hmgb1) oxidation in extracellular fluids studied by in situ protein nmr spectroscopy. J Biol Chem. 2013; 288(17):11621\u20137.","journal-title":"J Biol Chem"},{"issue":"4","key":"706_CR32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"J Palucka","year":"2012","unstructured":"Palucka J, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12(4):265\u201377.","journal-title":"Nat Rev Cancer"},{"issue":"211","key":"706_CR33","first-page":"1","volume":"12","author":"R Saenz","year":"2014","unstructured":"Saenz R, Futalan D, Leutenez L, Eekhout F, Fecteau JF, Sundelius S, et al.Tlr4-dependent activation of dendritic cells by an hmgb1-derived peptide adjuvant. J Transl Med. 2014; 12(211):1\u201311.","journal-title":"J Transl Med"},{"issue":"7","key":"706_CR34","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.4049\/jimmunol.1403134","volume":"194","author":"JMT Janco","year":"2015","unstructured":"Janco JMT, Lamichhane P, Karyampudi L, Knutson KL. Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol. 2015; 194(7):2985\u201391.","journal-title":"J Immunol"},{"key":"706_CR35","doi-asserted-by":"crossref","unstructured":"Ma Y, Shurin1 GV, Peiyuan Z, Shurin MR. Dendritic cells in the cancer microenvironment. J Cancer. 2013; 4(1):36\u201344.","DOI":"10.7150\/jca.5046"},{"issue":"2","key":"706_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5021\/ad.2013.25.2.135","volume":"25","author":"CY Perrot","year":"2013","unstructured":"Perrot CY, Javelaud D, Mauviel A. Insights into the transforming growth factor-beta signaling pathway in cutaneous melanoma. Ann Dermatol. 2013; 25(2):135\u201344.","journal-title":"Ann Dermatol"},{"key":"706_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/ITT.S55415","volume":"4","author":"TL Whiteside","year":"2015","unstructured":"Whiteside TL. The role of regulatory t cells in cancer immunology. Immunotargets Ther. 2015; 4:159\u201371.","journal-title":"Immunotargets Ther"},{"issue":"74","key":"706_CR38","first-page":"10","volume":"6","author":"L Shi","year":"2013","unstructured":"Shi L, Chen S, Yang L, Li Y. The role of pd-1 and pd-l1 in t-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013; 6(74):10\u2013118617568722674.","journal-title":"J Hematol Oncol"},{"key":"706_CR39","first-page":"47","volume":"4","author":"MR Muppidi","year":"2015","unstructured":"Muppidi MR, George S. Immune checkpoint inhibitors in renal cell carcinoma. J Target Ther Cancer 2015. 2015; 4:47\u201352.","journal-title":"J Target Ther Cancer 2015"},{"issue":"36","key":"706_CR40","first-page":"1","volume":"4","author":"V Umansky","year":"2016","unstructured":"Umansky V, Blattner C, Gebhardt C, Utikal J. The role of myeloid-derived suppressor cells (mdsc) in cancer progression. Vaccines. 2016; 4(36):1\u201316.","journal-title":"Vaccines"},{"key":"706_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jtbi.2012.03.024","volume":"303","author":"B Szomolay","year":"2012","unstructured":"Szomolay B, Eubank TD, Roberts RD, Marsh CB, Friedman A. Modeling the inhibition of breast cancer growth by gm-csf. J Theor Biol. 2012; 303:141\u2013151.","journal-title":"J Theor Biol"},{"issue":"3","key":"706_CR42","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3390\/cancers6031670","volume":"6","author":"T Chanmee","year":"2014","unstructured":"Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. 2014; 6(3):1670\u201390.","journal-title":"Cancers"},{"issue":"4","key":"706_CR43","first-page":"0153508","volume":"11","author":"W Hao","year":"2016","unstructured":"Hao W, Friedman A. Serum upar as biomarker in breast cancer recurrence: A mathematical model. PLoS ONE. 2016; 11(4):0153508.","journal-title":"PLoS ONE"},{"issue":"11","key":"706_CR44","first-page":"2752","volume":"74","author":"D Chen","year":"2012","unstructured":"Chen D, Roda JM, Marsh CB, Eubank TD, Friedman A. Hypoxia inducible factors-mediated inhibition of cancer by gm-csf: a mathematical model. Bull Math Biol. 2012; 74(11):2752\u201377.","journal-title":"Bull Math Biol"},{"key":"706_CR45","unstructured":"Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH, et al.Human pd-l1\/b7-h1\/cd274 protein. Sino Biological Inc. \n                    http:\/\/www.sinobiological.com\/PD-L1-B7-H1-CD274-Protein-g-533.html\n                    \n                  ."},{"key":"706_CR46","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH. The pd-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010; 236:219\u201342.","journal-title":"Immunol Rev"},{"issue":"47","key":"706_CR47","doi-asserted-by":"publisher","first-page":"6506","DOI":"10.1073\/pnas.1519623112","volume":"112","author":"RL Mautea","year":"2015","unstructured":"Mautea RL, Gordona SR, Mayere AT, McCrackena MN, Natarajane A, Ring NG, et al.Engineering high-affinity pd-1 variants for optimized immunotherapy and immuno-pet imaging. Proc Natl Acad Sci USA. 2015; 112(47):6506\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"706_CR48","volume-title":"Computational Methods for PDE in Mechanics. Series on Advances in Mathematics for Applied Sciences-Vol.67","author":"B D\u2019Acunto","year":"2004","unstructured":"D\u2019Acunto B. Computational Methods for PDE in Mechanics. Series on Advances in Mathematics for Applied Sciences-Vol.67. Singapore: Word Scientific; 2004."},{"issue":"1","key":"706_CR49","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jtbi.2008.04.011","volume":"254","author":"S Marino","year":"2008","unstructured":"Marino S, Hogue I, Ray C, Kirschner D. A methodology for performing global uncertainty and sensitivity analysis in systems biology. J Theor Biol. 2008; 254(1):178\u201396.","journal-title":"J Theor Biol"},{"issue":"16","key":"706_CR50","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/jnci\/djr246","volume":"103","author":"R W. Humphrey","year":"2011","unstructured":"W. Humphrey R, M Brockway-Lunardi L, T Bonk D, Dohoney KM, Doroshow JH, Meech SJ, Ratain MJ, Topalian SL, M Pardoll D. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011; 103(16):1222\u20136.","journal-title":"J Natl Cancer Inst"},{"issue":"Supplement 6","key":"706_CR51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1634\/theoncologist.2002-0013","volume":"7","author":"D Miles","year":"2002","unstructured":"Miles D, von Minckwitz G, Seidman AD. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist. 2002; 7(Supplement 6):13\u20139.","journal-title":"Oncologist"},{"issue":"4","key":"706_CR52","first-page":"1079","volume":"7","author":"K Fujimoto-Ouchi","year":"2001","unstructured":"Fujimoto-Ouchi K, Tanaka Y, Tominaga T. Schedule dependency of antitumor activity in combination therapy with capecitabine\/5?-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res. 2001; 7(4):1079\u201386.","journal-title":"Clin Cancer Res"},{"key":"706_CR53","first-page":"590","volume":"7","author":"E Frei III","year":"2003","unstructured":"Frei III E, Eder JP. Principles of dose, schedule, and combination therapy. Cancer Med. 2003; 7:590\u20139.","journal-title":"Cancer Med"},{"issue":"7","key":"706_CR54","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1586\/14737140.2014.920694","volume":"14","author":"G Cabibbo","year":"2014","unstructured":"Cabibbo G, Tremosini S, Galati G, Mazza G, Gadaleta-Caldarola G, Lombardi G, Antonucci M, Sacco R. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. Expert Rev Anticancer Ther. 2014; 14(7):831\u201345.","journal-title":"Expert Rev Anticancer Ther"},{"key":"706_CR55","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/bit.260220504","volume":"XXII","author":"ME Young","year":"1980","unstructured":"Young ME. Estimation of diffusion coefficients of proteins. Biotech Bioeng. 1980; XXII:947\u201355.","journal-title":"Biotech Bioeng"},{"issue":"9","key":"706_CR56","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1167\/iovs.02-1226","volume":"44","author":"YB Shui","year":"2003","unstructured":"Shui YB, Wang X, Hu JS, Wang SP, Garcia CM, et al.Vascular endothelial growth factor expression and signaling in the lens. Invest Ophthalmol Vis Sci. 2003; 44(9):3911\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"706_CR57","doi-asserted-by":"publisher","first-page":"91844","DOI":"10.1371\/journal.pone.0091844","volume":"9","author":"KL Liao","year":"2014","unstructured":"Liao KL, Bai XF, Friedman A. Mathematical modeling of interleukin-27 induction of anti-tumor t cells response. PLoS ONE. 2014; 9(3):91844.","journal-title":"PLoS ONE"},{"issue":"4","key":"706_CR58","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/tea.2006.0361","volume":"14","author":"C Androjna","year":"2008","unstructured":"Androjna C, Gatica JE, Belovich JM, Derwin KA. Oxygen diffusion through natural extracellular matrices: implications for estimating critical thickness values in tendon tissue engineering. Tissue Eng A. 2008; 14(4):559\u201369.","journal-title":"Tissue Eng A"},{"issue":"5","key":"706_CR59","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s11538-017-0254-9","volume":"80","author":"A Friedman","year":"2017","unstructured":"Friedman A, Hao W. The role of exosomes in pancreatic cancer microenvironment. Bull Math Biol. 2017; 80(5):1111\u2013113.","journal-title":"Bull Math Biol"},{"issue":"10","key":"706_CR60","doi-asserted-by":"publisher","first-page":"107511","DOI":"10.1371\/journal.pone.0107511","volume":"9","author":"D Chen","year":"2014","unstructured":"Chen D, Bobko AA, Gross AC, Evans R, Marsh CB, Khramtsov VV, et al.Involvement of tumor macrophage hifs in chemotherapy effectiveness: mathematical modeling of oxygen, ph, and glutathione. PLoS ONE. 2014; 9(10):107511.","journal-title":"PLoS ONE"},{"issue":"11","key":"706_CR61","first-page":"0165782","volume":"11","author":"W. -C Lo","year":"2016","unstructured":"Lo W. -C, Arsenescu V, Arsenescu RI, Friedman A. Inflammatory bowel disease: How effective is tnf-alpha suppression?. PLoS One. 2016; 11(11):0165782.","journal-title":"PLoS One"},{"key":"706_CR62","unstructured":"Abcam\/. Anti-pd1 antibody (ab89828). \n                    http:\/\/www.abcam.com\/pd1-antibody-ab89828.html\n                    \n                  ."},{"issue":"943409","key":"706_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/943409","volume":"2013","author":"S Agrawal","year":"2013","unstructured":"Agrawal S, Joshi M, Christoforidis JB. Vitreous inflammation associated with intravitreal anti-vegf pharmacotherapy. Mediat Inflamm. 2013; 2013(943409):1\u20136.","journal-title":"Mediat Inflamm"},{"issue":"3","key":"706_CR64","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jtbi.2009.06.025","volume":"260","author":"Y Kim","year":"2009","unstructured":"Kim Y, Lawler S, Nowicki MO, Chiocca EA, Friedman A. A mathematical model for pattern formation of glioma cells outside the tumor spheroid core. J Theor Biol. 2009; 260(3):359\u201371.","journal-title":"J Theor Biol"},{"issue":"3","key":"706_CR65","first-page":"401","volume":"61","author":"Y Kim","year":"2010","unstructured":"Kim Y, Wallace J, Li F, Ostrowski M, Friedman A. Transformed epithelial cells and fibroblasts\/myofibroblasts interaction in breast tumor: a mathematical model and experiments. J Theor Biol. 2010; 61(3):401\u201321.","journal-title":"J Theor Biol"}],"container-title":["BMC Systems Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12918-019-0706-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12918-019-0706-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12918-019-0706-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T10:55:27Z","timestamp":1589540127000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsystbiol.biomedcentral.com\/articles\/10.1186\/s12918-019-0706-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,13]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1186\/s12918-019-0706-y","relation":{},"ISSN":["1752-0509"],"issn-type":[{"value":"1752-0509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,13]]},"assertion":[{"value":"26 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"30"}}